Breast Cancer Nerve Recruitment Discovery
Analysis based on 6 articles · First reported Aug 04, 2026 · Last updated Aug 25, 2026
The discovery could lead to new treatments for triple-negative breast cancer by targeting BDNF signaling, potentially expanding the market for existing drugs. Biotech and pharma companies developing cancer therapies may see increased interest, while the University of Oklahoma's research reputation could strengthen.
Researchers at the University of Oklahoma discovered that triple-negative breast cancer tumors recruit macrophages, which then release brain-derived neurotrophic factor (BDNF), attracting nerves into the tumor. Blocking BDNF signaling in mice reduced nerve infiltration and slowed tumor growth. Patient data showed higher macrophage and BDNF levels correlated with poorer survival. The study was published in Cell Death & Differentiation and funded by the United States — National Institutes of Health and Oklahoma's Tobacco Settlement Endowment Trust. The team plans to test the approach in ovarian cancer.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard